Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
A warehouse of patient-donated biological data expedites trial accrual, reduces trial sizes, saves money, and may speed drugs through the drug development pipeline.
A new study shows a significant correlation between poorer performance on neuropsychological tests and memory complaints in posttreatment, early-stage breast cancer patients—particularly those who have undergone combined chemotherapy and radiation.
Older individuals with nonmelanoma skin cancer seem to have a significantly reduced risk of developing Alzheimer's disease, according to a Neurology study.
The biggest challenges in incorporating biomarker testing into lung cancer care occur when a tissue sample is of insufficient size or quality.
Pioneering biophotonics technology is the first screening method to detect the early presence of ovarian cancer in humans
Genetech announced results from CLL11, a Phase 3 study of obinutuzumab (GA101), comparing the combination of either obinutuzumab or Rituxan and chlorambucil to chlorambucil alone in chronic lymphocytic leukemia (CLL).
Gilead announced Phase 2 results for idelalisib, an oral inhibitor of PI3K delta in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia.
Findings show younger cancer patients are increasingly vulnerable to bankruptcy.
Research shows discrepancies in the way the role of nurse practitioners is viewed.
Orally administered rigosertib was found to be well-tolerated in patients with advanced solid tumors in a phase 1 trial. Rigosertib is a dual kinase inhibitor, and this trial is the first to study its orally administered form in solid tumors.
Later-stage breast cancers tend to have more mutations and are more heterogeneous than early-stage cancers. Now, new findings demonstrate that heterogeneity is prevalent even within legions of DCIS.
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors.
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy. A new study identified gene variations that can predispose people to chemotherapy-induced peripheral neuropathy.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|